Washing method for extracellular vesicles
Washing extracellular vesicles with nonionic surfactants like alcohol ethoxylates or polyoxyethylene-polyoxypropylene block copolymers addresses contamination issues, enhancing the accuracy of marker detection within the vesicles.
Patent Information
- Application Number
- JP2021520800
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-05-21
- Filing Date
- 2020-05-19
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-05-19
AI Technical Summary
The detection of substances within extracellular vesicles is hindered by contamination from substances outside the vesicles, which overwhelm the target substances inside, leading to inaccurate measurements.
A method involving washing extracellular vesicles with a nonionic surfactant, such as alcohol ethoxylates or polyoxyethylene-polyoxypropylene block copolymers, to reduce contamination and enhance the detection accuracy of markers within the vesicles.
The method effectively reduces contaminants, improving the accuracy of detection and measurement of extracellular vesicle markers, enabling more precise analysis and diagnosis.
Smart Images

Figure 0007581193000024 
Figure 0007581193000001 
Figure 0007581193000002
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for washing extracellular vesicles, etc. [Background technology]
[0002] Extracellular vesicles (EVs) are minute vesicles with a membrane structure secreted from various types of cells, and are present in body fluids such as blood or cell culture fluids. Extracellular vesicles secreted outside cells include exosomes, ectosomes, and apoptotic blebs. Extracellular vesicles are a diverse group containing various substances that perform functions such as intercellular signaling, and are therefore analyzed for the purpose of diagnosis, drug discovery, and the like. Therefore, there is a demand for the development of a washing method for extracellular vesicles that is useful for such analyses. For example, Patent Document 1 describes a method for isolating EVs in which a nonionic surfactant is added during immunoprecipitation and / or washing to reduce aggregation between solid phase carriers. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] International Publication No. 2015 / 068772 Summary of the Invention [Problem to be solved by the invention]
[0004] When detecting a substance contained in EVs in a specimen such as a body fluid, the substance may be present in large amounts outside the EVs in the specimen. In general, the amount of the target substance contained in EVs is small compared to the amount of the same substance present outside the EVs in the specimen. Therefore, when detecting or measuring the target substance in EVs recovered from a specimen, the target substance present in large amounts outside the EVs in the body fluid is mixed in as a contaminant and becomes background, making it difficult to detect or measure the target substance in EVs. For example, it has been reported that measuring CEA, a cancer marker in EVs, improves diagnostic performance, but when detecting or measuring CEA in EVs derived from blood specimens, CEA is contained in much larger amounts in blood specimens than in EVs, so if CEA outside the EVs is adsorbed on the EV surface or container surface as a contaminant, the target substance, CEA in the EVs, cannot be accurately detected or measured.
[0005] Therefore, an object of the present invention is to develop a method that can reduce the inclusion of contaminants in a system for manipulating extracellular vesicles. [Means for solving the problem]
[0006] As a result of extensive research, the inventors discovered that by washing EVs with a cleaning solution containing a specific nonionic surfactant, it is possible to reduce the amount of contaminants such as the same target substance (e.g., the same substance as the target substance to be detected or measured) contained outside the EVs, and thus completed the present invention.
[0007] That is, the present invention is as follows. [1] Extracellular vesicles are classified into -O-(-CH2-CH2-O-) x A method for washing extracellular vesicles, comprising washing with a nonionic surfactant which is a chain compound having a structure represented by the formula: -H (wherein x is 1 to 300). [2] The method according to [1], wherein the nonionic surfactant is an alcohol ethoxylate. [3] The method according to [2], wherein the alcohol ethoxylate is a compound represented by formula (I): [ka] In the formula, x is 15 to 100; y is an integer equal to or greater than 0; z is an integer equal to or greater than 0; y≧z; y+z is between 5 and 30. [4] The method according to [2] or [3], wherein the alcohol ethoxylate is an alcohol ethoxylate having an HLB of 15 or more or a carbon chain having 16 or less carbon atoms. [5] The method according to [1], wherein the nonionic surfactant is a polyoxyethylene-polyoxyalkylene block copolymer. [6] The method according to [5], wherein the polyoxyethylene-polyoxyalkylene block copolymer is a polyoxyethylene-polyoxypropylene block copolymer represented by formula (III): [ka] In the formula, x2 is an integer of 1 or more; y2 is 10 to 100; z2 is an integer equal to or greater than 1; x2+z2 is between 20 and 300. [7] Any of the methods according to [1] to [6], wherein the extracellular vesicles are treated with 0.001 to 10.0 w / v% of the nonionic surfactant. [8] Any of the methods according to [1] to [7], wherein the extracellular vesicles are exosomes. [9] Any of the methods according to [1] to [8], wherein washing the extracellular vesicles with the nonionic surfactant comprises washing a complex between the extracellular vesicles and an extracellular vesicle membrane-bound substance with the nonionic surfactant.
[10] Any of the methods according to [1] to [9], wherein the extracellular vesicle membrane-binding substance is an antibody against a tetraspanin membrane protein.
[11] A method for producing a purified extracellular vesicle, comprising: (1) Extracellular vesicles are converted to -O-(-CH2-CH2-O-) x -H, wherein x is 1 to 300; and (2) Isolating the washed extracellular vesicles.
[12] The method according to
[11] , wherein the nonionic surfactant is an alcohol ethoxylate or a polyoxyethylene-polyoxypropylene block copolymer.
[13] The method according to
[11] or
[12] , which is carried out by the steps of: (1') treating extracellular vesicles with an extracellular vesicle membrane-binding substance to form a complex between the extracellular vesicles and the extracellular vesicle membrane-binding substance; (2') washing the complex with the nonionic detergent; and (3') isolating the complex.
[14] A method for analyzing extracellular vesicles, comprising analyzing extracellular vesicles washed by any of the methods of [1] to
[10] , or a purified product of extracellular vesicles produced by any of the methods of
[11] to 13].
[15] The method of
[14] , wherein the analysis is performed by detection of an extracellular vesicle internal marker.
[16] The method of
[15] , wherein the extracellular vesicle internal marker is carcinoembryonic antigen (CEA) or CA125.
[17] Any of the methods according to
[14] to
[16] , which is carried out by the steps of: (1) Destroying extracellular vesicles washed by any one of the methods [1] to
[10] or extracellular vesicle purified products produced by any one of the methods
[11] to
[13] ; and (2) To detect extracellular vesicle internal markers in disrupted extracellular vesicles.
[18] A kit comprising: (1) -O-(-CH2-CH2-O-) x a nonionic surfactant which is a chain compound containing a structure represented by the formula: (2) Extracellular vesicle membrane-bound substances. Effect of the Invention
[0008] According to the present invention, the inclusion of contaminants can be reduced by washing extracellular vesicles with a specific nonionic surfactant. Reduction of the inclusion of contaminants reduces obstacles such as background in the detection or measurement of extracellular vesicle markers, improving the accuracy of detection or measurement. Therefore, the present invention is useful for high-precision analysis or diagnosis when using extracellular vesicle markers as indicators. In addition, the present invention is useful for recovering extracellular vesicles that serve as samples for high-precision analysis or diagnosis. [Brief description of the drawings]
[0009] [Figure 1] FIG. 1 shows a concentration-dependent comparison of the washing effect of Tergitol 15-s-30 and Pluronic F68 in EV recovery using the residual total protein as an indicator in Example 6. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] 1. Classification of surfactants In the present invention, multiple types of surfactants can be used depending on one or more purposes (e.g., EV cleaning, EV destruction). Therefore, to determine the selection of a surfactant suitable for each purpose, surfactants are classified based on their chemical properties (ionic properties of the hydrophilic part) and functional properties (properties / use for EVs).
[0011] 1-1. Classification of surfactants based on the ionic properties of the hydrophilic part Surfactants can be classified based on the ionic character of the hydrophilic portion into nonionic, cationic, anionic, and zwitterionic surfactants. Examples of each surfactant are given below.
[0012] 1-1-1.Nonionic surfactants Examples of the nonionic surfactant include polyoxyethylene alcohol structure-containing nonionic surfactants (e.g., alcohol ethoxylates, polyoxyethylene-polyoxyalkylene block copolymers), polyoxyethylene sorbitan fatty acid esters (e.g., TWEEN (registered trademark) series (e.g., TWEEN20, TWEEN40, TWEEN80)), polyoxyethylene octylphenyl ethers (e.g., TRITON (registered trademark) series (e.g., Triton X-100, Triton X-114, Triton X-305, Triton X-405, Triton X-705)), and ND-gluco-N-methylalkanamides (e.g., MEGA series (e.g., MEGA 8, MEGA 10).
[0013] "Nonionic surfactants containing a polyoxyethylene alcohol structure" are -O-(-CH2-CH2-O-) x -H (wherein x is an integer of 1 or more) (hereinafter referred to as "polyoxyethylene alcohol structure") is a chain compound (a compound not including a cyclic structure). Such a compound may be either a straight-chain compound or a branched-chain compound. Such a compound may consist of a single bond or may contain multiple bonds. Such a compound may contain one or more (e.g., 2, 3, 4) polyoxyethylene alcohol structures. Examples of structures other than the polyoxyethylene alcohol structure in such a compound include an alkylene structure (straight-chain or branched chain) and a polyoxyalkylene structure (straight-chain or branched chain). Such a compound may consist of carbon atoms, hydrogen atoms, and oxygen atoms. Examples of such compounds include alcohol ethoxylates and polyoxyethylene-polyoxyalkylene block copolymers (e.g., polyoxyethylene-polyoxypropylene block copolymers).
[0014] "Alcohol ethoxylates" refers to a class of compounds represented by formula (I):
[0015] [ka]
[0016] In the formula, x is an integer equal to or greater than 1; y is an integer equal to or greater than 0; z is an integer equal to or greater than 0; y≧z.
[0017] In formula (I), "H-(-CH2-) y -CH-(-CH2-) z The portion represented by "-H" may be called the "hydrophobic side chain", "carbon chain", "alkyl chain", or the like. In formula (I), the number of carbon atoms in the hydrophobic side chain corresponds to y+z+1. In formula (I), "-(-CH2-CH2-O-) x The portion represented by "-H" is sometimes called the "hydrophilic side chain" or "ethoxylate chain", etc.
[0018] Alcohol ethoxylates include, for example, branched chain alcohol ethoxylates and straight chain alcohol ethoxylates.
[0019] A branched alcohol ethoxylate corresponds to a compound represented by the above formula (I) in which y is an integer of 1 or more and z is an integer of 1 or more. Examples of branched alcohol ethoxylate include polyoxyethylene (3) sec-tridecyl ether, polyoxyethylene (7) sec-tridecyl ether, polyoxyethylene (9) sec-tridecyl ether, polyoxyethylene (12) sec-tridecyl ether, polyoxyethylene (15) sec-tridecyl ether, polyoxyethylene (20) sec-tridecyl ether, polyoxyethylene (30) sec-tridecyl ether, and polyoxyethylene (40) sec-tridecyl ether. Examples of branched alcohol ethoxylates include commercially available TERGITOL (registered trademark) series compounds such as Tergitol15-S-3, Tergitol15-S-5, Tergitol15-S-7, Tergitol15-S-9, Tergitol15-S-12, Tergitol15-S-15, Tergitol15-S-20, Tergitol15-S-30, and Tergitol15-S-40. The TERGITOL15-S series has an alkyl chain with a carbon atom number (y+z+1) of 11 to 15 (average 13), and the number after "S" in the system name represents the number of ethylene oxide units (x) in the ethoxylate chain.
[0020] The linear alcohol ethoxylate corresponds to a compound represented by the above formula (I) in which z is 0. Examples of linear alcohol ethoxylate include polyoxyethylene (4) lauryl ether, polyoxyethylene (23) lauryl ether, polyoxyethylene (20) cetyl ether, and polyoxyethylene (20) stearyl ether. Commercially available linear alcohol ethoxylates include compounds of the BRIJ (registered trademark) series, such as Brij 30, Brij 35, Brij 58, and Brij 78. The linear alcohol ethoxylate can also be represented by the following formula (II).
[0021] [ka]
[0022] In the formula, x is an integer equal to or greater than 1; n is an integer of 1 or greater.
[0023] The term "polyoxyethylene-polyoxyalkylene block copolymer" refers to a block copolymer containing a polyoxyethylene block and a polyoxyalkylene block. An example of the polyoxyethylene-polyoxyalkylene block copolymer is a polyoxyethylene-polyoxypropylene block copolymer.
[0024] The term "polyoxyethylene-polyoxypropylene block copolymer" refers to a group of compounds represented by the following formula (III).
[0025] [ka]
[0026] In the formula, x2, y2, and z2 are integers of 1 or more.
[0027] Examples of polyoxyethylene-polyoxypropylene block copolymers include poloxamer 182, poloxamer 108, poloxamer 188, poloxamer 217, poloxamer 237, poloxamer 238, poloxamer 288, poloxamer 388, and poloxamer 407. Commercially available polyoxyethylene-polyoxypropylene block copolymers include compounds of the PLURONIC (registered trademark) series, such as Pluronic L62, Pluronic F38, Pluronic F68, Pluronic F77, Pluronic F87, Pluronic F88, Pluronic F98, Pluronic F108, and Pluronic F127.
[0028] 1-1-2. Cationic surfactants Examples of cationic surfactants include quaternary ammonium salts. Examples of salts include salts with halogens (e.g., fluorine, chlorine, bromine, iodine). Examples of quaternary ammonium salts include Cn alkyl trimethyl ammonium bromide (CnTAB) and Cn alkyl trimethyl ammonium chloride (CnTAC). Examples of CnTAB include octyl trimethyl ammonium bromide (C8TAB), nonyl trimethyl ammonium bromide (C9TAB), dodecyl trimethyl ammonium bromide (C12TAB), tetradecyl trimethyl ammonium bromide (C14TAB), and hexadecyl trimethyl ammonium bromide (C16TAB). Examples of CnTAC include dodecyltrimethylammonium chloride (C12TAC), tetradecyltrimethylammonium chloride (C14TAC), hexadecyltrimethylammonium chloride (C16TAC), and octadecyltrimethylammonium chloride (C18TAC).
[0029] 1-1-3. Anionic surfactants Examples of anionic surfactants include carboxylic acid surfactants (e.g., N-decanoyl sarcosine sodium (NDS), N-lauroyl sarcosine sodium hydrate (NLS)), sulfonic acid surfactants (e.g., 1-sodium nonanesulfonate (NSS), sodium dodecylbenzenesulfonate (SDBS)), carboxylic acid-sulfonic acid surfactants (e.g., sodium chondroitin sulfate (CSSS)), and sulfate ester surfactants (e.g., sodium dodecyl sulfate (SDS)).
[0030] 1-1-4. Zwitterionic surfactants Examples of amphoteric surfactants include quaternary ammonium-sulfonic acid surfactants. Examples of quaternary ammonium-sulfonic acid surfactants include 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate (CHAPSO), 3-(N,N-dimethyloctylammonio)propanesulfonate (C8APS), 3-(decyldimethylammonio)propanesulfonate (C10APS), N-dodecyl-N,N-dimethyl-3-ammonio 1-propanesulfonate (C12APS), 3-(N,N-dimethylmyristylammonio)propanesulfonate (C14APS), 3-(N,N-dimethylpalmitylammonio)propanesulfonate (C16APS), dimethylethylammonium propanesulfonate (NDSB-195), 3-[dimethyl-(2-hydroxyethyl)ammonio]-1-propanesulfonate (NDSB-211), 3-(benzenedimethylammonio)propanesulfonate (NDSB-256).
[0031] 1-1-5. Physical properties of surfactants The HLB (Hydrophilic-Lipophilic Balance) value can be used as a physical property value representing the hydrophilicity and lipophilicity of a surfactant. The closer the HLB value is to 0, the higher the lipophilicity. The HLB value of a commercially available compound may be the value listed on the manufacturer's data sheet. The HLB value listed on the manufacturer's data sheet may exceed 20. The HLB value of an alcohol ethoxylate may be determined, for example, simply by the Griffin method.
[0032] 1-1-6. Summary of surfactant classification based on ionic properties Classification of surfactants based on the ionic properties of the hydrophilic portion is summarized in the table below.
[0033] [Table 1-1]
[0034] [Table 1-2]
[0035] Classification of surfactants based on their properties and applications to EVs Surfactants can be classified into "EV-resistant surfactants" and "EV-destroying surfactants" based on the degree of their EV-destroying properties. Among the "EV-resistant surfactants," those that have a cleaning effect can be further classified as "EV-cleaning surfactants." By selecting an EV-cleaning surfactant from among the EV-resistant surfactants, it is possible to clean EVs and EV operation systems while preventing the release of EV internal markers outside the EV due to EV destruction. Among the "EV-cleaning surfactants," those that fall under the category of nonionic surfactants are called "EV-cleaning nonionic surfactants." The above classification can be performed, for example, based on the method described in the examples of this specification.
[0036] 2. Washing method for extracellular vesicles The present invention provides a method for washing extracellular vesicles.
[0037] Extracellular vesicles are minute vesicles having a membrane structure secreted from various types of cells. Examples of extracellular vesicles include exosomes, ectosomes, and apoptotic vesicles. Preferably, the extracellular vesicles are exosomes. The extracellular vesicles can also be defined by their size. The size of the extracellular vesicles is, for example, 30 to 1000 nm, preferably 50 to 300 nm, and more preferably 80 to 200 nm. The size of the extracellular vesicles can be measured by, for example, a method based on the Brownian motion of the extracellular vesicles, a light scattering method, an electrical resistance method, or the like. Preferably, the size of the extracellular vesicles is measured by NanoSight (manufactured by Malvern Instruments).
[0038] The washing method of the present invention includes washing extracellular vesicles with an "EV-washing nonionic surfactant". The "EV-washing nonionic surfactant" used in the washing method of the present invention is a polyoxyethylene alcohol structure-containing nonionic surfactant.
[0039] The polyoxyethylene alcohol structure-containing nonionic surfactant used as the EV cleaning nonionic surfactant in the cleaning method of the present invention is -O-(-CH2-CH2-O-) x It is a chain compound (a compound not including a cyclic structure) containing a structure represented by -H (polyoxyethylene alcohol structure). x is an integer of 1 or more, for example, 1 to 300. Such a compound may be either a straight-chain compound or a branched-chain compound. Such a compound may be composed of a single bond or may contain multiple bonds, but is preferably composed of a single bond. Such a compound may contain one or more (e.g., 2, 3, or 4) polyoxyethylene alcohol structures. Examples of structures other than the polyoxyethylene alcohol structure in such a compound include an alkyl structure (straight-chain or branched-chain) and a polyoxyalkylene structure (straight-chain or branched-chain). The alkyl structure may be, for example, C 6~31 It may be an alkyl structure, C 6~31 A linear alkyl structure is preferred. The alkylene in the polyoxyalkylene structure is, for example, 1~6 It may be an alkylene group. 1~6 Examples of the alkylene group include C1 alkylene group (methylene group), C2 alkylene group (ethylene group, ethylidene group), C3 alkylene group (propylidene group, propylene group, trimethylene group, isopropylidene group), C4 alkylene group (e.g., tetramethylene group), C5 alkylene group (e.g., pentamethylene group), and C6 alkylene group (e.g., hexamethylene group). Such compounds may be composed of carbon atoms, hydrogen atoms, and oxygen atoms. Examples of such compounds include alcohol ethoxylates and polyoxyethylene-polyoxyalkylene block copolymers (e.g., polyoxyethylene-polyoxypropylene block copolymers).
[0040] An "alcohol ethoxylate" is a compound represented by the following formula (I):
[0041] [ka]
[0042] In the formula, x is an integer equal to or greater than 1; y is an integer equal to or greater than 0; z is an integer equal to or greater than 0; y≧z.
[0043] The alcohol ethoxylates used as EV cleansing nonionic surfactants in the cleaning methods of the present invention may be either branched or linear alcohol ethoxylates.
[0044] Such branched alcohol ethoxylates correspond to compounds represented by the above formula (I) in which y is an integer of 1 or more and z is an integer of 1 or more. Examples of such branched alcohol ethoxylates include polyoxyethylene (7) sec-tridecyl ether, polyoxyethylene (9) sec-tridecyl ether, polyoxyethylene (15) sec-tridecyl ether, polyoxyethylene (20) sec-tridecyl ether, polyoxyethylene (30) sec-tridecyl ether, and polyoxyethylene (40) sec-tridecyl ether. Examples of such branched alcohol ethoxylates include commercially available compounds of the TERGITOL (registered trademark) series, such as Tergitol 15-S-7, Tergitol 15-S-9, Tergitol 15-S-15, Tergitol 15-S-20, Tergitol 15-S-30, and Tergitol 15-S-40.
[0045] Such linear alcohol ethoxylate corresponds to a compound represented by the above formula (I) in which z is 0. Examples of such linear alcohol ethoxylate include commercially available BRIJ (registered trademark) series compounds such as Brij 35, Brij 58, and Brij 78. The linear alcohol ethoxylate can also be represented by the following formula (II).
[0046] [ka]
[0047] In the formula, x is an integer equal to or greater than 1; n is an integer of 1 or greater.
[0048] The alcohol ethoxylate used as the EV cleaning nonionic surfactant in the cleaning method of the present invention is a compound represented by formula (I): x is between 15 and 100; y is an integer equal to or greater than 0; z is an integer equal to or greater than 0; y≧z; y+z is between 5 and 30 Compounds are preferred.
[0049] The alcohol ethoxylate used as the EV cleaning nonionic surfactant in the cleaning method of the present invention is preferably an alcohol ethoxylate with HLB of 15 or more or with a carbon chain of 16 or less carbon atoms. The alcohol ethoxylate used in the cleaning method of the present invention is more preferably an alcohol ethoxylate with HLB of 15 or more. Preferred examples of the alcohol ethoxylate used in the cleaning method of the present invention include Tergitol15-S-15, Tergitol15-S-20, Tergitol15-S-30, Tergitol15-S-40, Brij35, Brij58, and Brij78. More preferred examples of the alcohol ethoxylate used in the cleaning method of the present invention include Tergitol15-S-30, Tergitol15-S-40, Brij35, and Brij58.
[0050] A "polyoxyethylene-polyoxyalkylene block copolymer" is a block copolymer containing a polyoxyethylene block and a polyoxyalkylene block. The alkylene in the polyoxyalkylene block is, for example, C 1~6 It may be an alkylene group, for example, a C1 alkylene group (methylene group), a C2 alkylene group (ethylene group, ethylidene group), a C3 alkylene group (propylidene group, propylene group, trimethylene group, isopropylidene group), a C4 alkylene group (e.g., tetramethylene group), a C5 alkylene group (e.g., pentamethylene group), a C6 alkylene group (e.g., hexamethylene group). An example of a polyoxyethylene-polyoxyalkylene block copolymer is a block copolymer having a structure of HO-[polyoxyethylene block]-[polyoxyalkylene block]-[polyoxyethylene block]-H. The polyoxyethylene-polyoxyalkylene block copolymer may preferably be a polyoxyethylene-polyoxypropylene block copolymer.
[0051] "Polyoxyethylene-polyoxypropylene block copolymers" are a group of compounds represented by the following formula (III).
[0052] [ka]
[0053] In the formula, x2, y2, and z2 are integers of 1 or more.
[0054] Examples of polyoxyethylene-polyoxypropylene block copolymers include poloxamer 188 and poloxamer 407. Commercially available polyoxyethylene-polyoxypropylene block copolymers include compounds of the PLURONIC (registered trademark) series, such as Pluronic F68 and Pluronic F127.
[0055] The polyoxyethylene-polyoxypropylene block copolymer used as the EV cleaning nonionic surfactant in the cleaning method of the present invention is a compound represented by formula (III): x2 is an integer greater than or equal to 1; y2 is 10 to 100; z2 is an integer equal to or greater than 1; x2+z2 is between 20 and 300 Compounds are preferred.
[0056] The polyoxyethylene-polyoxypropylene block copolymer used as the EV cleaning nonionic surfactant in the cleaning method of the present invention is preferably a polyoxyethylene-polyoxypropylene block copolymer having an HLB of 15 or more. Preferred examples of the polyoxyethylene-polyoxypropylene block copolymer used in the cleaning method of the present invention include poloxamer 188 (e.g., Pluronic F68), poloxamer 108 (e.g., Pluronic F38), poloxamer 217 (e.g., Pluronic F77), poloxamer 237 (e.g., Pluronic F87), poloxamer 238 (e.g., Pluronic F88), poloxamer 288 (e.g., Pluronic F98), poloxamer 388 (e.g., Pluronic F108), and poloxamer 407 (e.g., Pluronic F127). More preferred examples of the polyoxyethylene-polyoxypropylene block copolymer used in the cleaning method of the present invention include poloxamer 188 (eg, Pluronic F68) and poloxamer 407 (eg, Pluronic F127).
[0057] The non-ionic surfactant used as the EV cleansing non-ionic surfactant in the cleaning method of the present invention is preferably an alcohol ethoxylate.
[0058] The concentration of the EV-cleaning nonionic surfactant in washing the extracellular vesicles is not particularly limited as long as it is a concentration that can suppress the adsorption of contaminants to the extracellular vesicles and the system for manipulating the extracellular vesicles and can suppress the destruction of the extracellular vesicles. Such a concentration varies depending on the type of the EV-cleaning nonionic surfactant, but is, for example, 0.001 to 10.0 w / v%. Preferably, the concentration of the EV-cleaning nonionic surfactant may be 0.002 w / v% or more, 0.005 w / v% or more, or 0.01 w / v% or more. Such a concentration also varies depending on the type of the EV-cleaning nonionic surfactant, but may be 7.5 w / v% or less, 5.0 w / v% or less, or 2.0 w / v% or less. More preferably, the concentration of the EV-cleaning nonionic surfactant may be 0.002 to 7.5 w / v%, 0.005 to 5.0 w / v%, or 0.01 to 2.0 w / v%.
[0059] The EV cleaning nonionic surfactant used in the cleaning method of the present invention may be an aqueous solution. Examples of the aqueous solution include water (e.g., distilled water, sterile water, sterile distilled water, and pure water) and buffer solutions, with buffer solutions being preferred. Examples of the buffer solution include phosphate buffer, phosphate buffered saline (PBS), tartrate buffer, citrate buffer, acetate buffer, glycine buffer, carbonate buffer, 2-morpholinoethanesulfonic acid (MES) buffer, trishydroxymethylaminomethane (Tris) buffer, borate buffer, 3-morpholinopropanesulfonic acid (MOPS) buffer, N,N-bis(2-hydroxyethyl)glycine (Bicine) buffer, bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane (Bis-Tris) buffer, and 2-[4-(2-hydroxyethyl)1-piperazinylethanesulfonic acid (HEPES) buffer. The pH of the buffer solution is preferably neutral. More specifically, such pH may be preferably 5.0 or more, more preferably 5.5 or more, and even more preferably 6.0 or more. The pH may also be preferably 9.0 or less, more preferably 8.5 or less, and even more preferably 8.0 or less. The pH can be measured using a method known in the art. Preferably, the pH can be measured at 25°C using a pH meter with a glass electrode.
[0060] The temperature in washing the extracellular vesicles may be, for example, 4 to 45°C, and preferably 15 to 40°C. The time in washing is not particularly limited as long as it is a time sufficient to suppress the adsorption of impurities to the extracellular vesicles, and may be, for example, 1 second or more, 5 seconds or more, 10 seconds or more, or 20 seconds or more. Such a time may also be 4 minutes or less, 2 minutes or less, or 1 minute or less. In washing the extracellular vesicles, after mixing the extracellular vesicles with the EV-washing nonionic surfactant, the mixture may be left to stand, may be stirred with a vortex mixer, or may be further mixed by pipetting.
[0061] In the present invention, "washing of extracellular vesicles" refers to reducing the amount of impurities on the surface of extracellular vesicles and in a system (e.g., a solution, a container) in which the extracellular vesicles are manipulated. Examples of impurities include proteins, nucleic acids (e.g., RNA, DNA), sugars, lipids, amino acids, vitamins, polyamines, and peptides. Impurities refer to contaminants that interfere with the analysis of extracellular vesicles, and include, for example, impurities that enhance the detection background (e.g., substances identical or similar to the detection target) and impurities that attenuate the detection signal (e.g., substances that inhibit the detection of the detection target). In washing of extracellular vesicles, it is preferable to reduce the amount of substances identical or similar to the detection target, and it is more preferable to reduce the total amount of substances belonging to the same category as the detection target (e.g., the total protein amount when the detection target is a protein). Examples of the manipulation of extracellular vesicles include washing of extracellular vesicles, production of purified products of extracellular vesicles (i.e., recovery of extracellular vesicles), and analysis of extracellular vesicles. Examples of containers for manipulating extracellular vesicles include containers made of materials such as plastic (e.g., polypropylene) and glass, and containers made of plastic are preferred.
[0062] The extracellular vesicles washed by the washing method of the present invention can be used for analysis. The analysis of extracellular vesicles may be, for example, the analysis of components (EV markers) contained in the extracellular vesicles. Examples of EV markers include EV internal markers and EV surface markers. Examples of EV internal markers include carcinoembryonic antigen (CEA), CA125, CA15-3, actin family, TSG101, ALIX, charged multivesicular body protein (CHMP) family, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), poly(ADP-ribose) polymerase (PARP) family, AFP, CA19-9, flotillin-I, flotillin-II, Rab proteins, programmed cell death (PDCD)6, phospholipid scramblase (PLSCR) family, cytochrome C oxidase (COX) family, lamin family, proliferating cell nuclear antigen (PCNA), tubulin family, TATA binding protein (TBP), voltage-dependent anion channel protein (VDAC), amyloid beta, and tau protein. Examples of EV surface markers include tetraspanin membrane proteins (extracellular vesicle membrane-specific four-spanning membrane proteins, e.g., CD9, CD63, CD81), extracellular matrix metalloproteinase inducers (e.g., CD147), heat shock protein (HSP) 70, HSP90, major histocompatibility complex (MHC) I, lysosomal-associated membrane protein (LAMP) 1, intercellular adhesion molecule (ICAM)-1, integrins, ceramide, cholesterol, phosphatidylserine, Annexins, Caveolin-I, and EpCAM.
[0063] The washing method of the present invention may be combined with a precipitation method (e.g., immunoprecipitation method) using an extracellular vesicle membrane-binding substance. In this case, after forming a complex (e.g., immunoprecipitation complex) between the extracellular vesicles and the extracellular vesicle membrane-binding substance (e.g., antibody) by the precipitation method, the complex may be washed with an EV-cleaning nonionic surfactant. In other words, washing the extracellular vesicles with an EV-cleaning nonionic surfactant may be washing the complex between the extracellular vesicles and the extracellular vesicle membrane-binding substance with an EV-cleaning nonionic surfactant.
[0064] The extracellular vesicle membrane-binding substance used in the present invention is a substance having affinity for the above-mentioned EV surface marker. Examples of the extracellular vesicle membrane-binding substance include antibodies (e.g., monoclonal antibodies, polyclonal antibodies) against the above-mentioned EV surface markers and their antigen-binding fragments, aptamers, phosphatidylserine-binding proteins, and ceramide-binding proteins. The antigen-binding fragment may be any antibody fragment that maintains binding to the target EV surface marker, and includes Fab, Fab', F(ab')2, scFv, and the like. The extracellular vesicle membrane-binding substance is preferably an antibody or an antigen-binding fragment thereof, and more preferably a monoclonal antibody or an antigen-binding fragment thereof. In addition, the extracellular vesicle membrane-binding substance used in the present invention may be one or a combination of multiple substances.
[0065] The extracellular vesicle membrane-binding substance may be bound to a solid phase to facilitate the separation of extracellular vesicles.For example, sepharose beads, agarose beads, magnetic beads (magnetic particles), or plastic plates can be used as the solid phase.The immobilization of the extracellular vesicle membrane-binding substance to the solid phase can be carried out by a conventional method well known to those skilled in the art.
[0066] 3. Method for producing purified extracellular vesicles The present invention also provides a method for producing a purified extracellular vesicle product.
[0067] The manufacturing method of the present invention comprises the following steps: (1) washing the extracellular vesicles with an “EV-detergent non-ionic detergent”; and (2) Isolating the washed extracellular vesicles.
[0068] The separation of extracellular vesicles in step (2) can be carried out, for example, by sedimentation using an extracellular vesicle membrane-binding substance or ultracentrifugation. The extracellular vesicles can be recovered by precipitating the extracellular vesicles by sedimentation or ultracentrifugation, and then recovering the precipitate or discarding the supernatant. The precipitate can be recovered by any method known in the art (e.g., magnetic collection of magnetic particles, centrifugation of sepharose beads). The separation is preferably isolation or purification.
[0069] When the separation of extracellular vesicles in step (2) is carried out by a precipitation method, the formation of a complex between the extracellular vesicles and the extracellular vesicle membrane-bound substance may be carried out before step (2). That is, in this case, the production method of the present invention may be carried out by the steps including the following: (1') treating extracellular vesicles with an extracellular vesicle membrane-binding substance to form a complex between the extracellular vesicles and the extracellular vesicle membrane-binding substance; (2') washing the complexes of extracellular vesicles and extracellular vesicle membrane-bound substances with an "EV-washing non-ionic detergent"; and (3') Separating the complex between the extracellular vesicles and the extracellular vesicle membrane-bound substances.
[0070] In the production method of the present invention, the extracellular vesicle purified product may be obtained in the form of a complex between the extracellular vesicle and the extracellular vesicle membrane-bound substance, or in the form of free extracellular vesicles. In order to obtain the extracellular vesicle purified product in a free form, the production method of the present invention may include a step of dissociating the extracellular vesicles from the complex. Dissociation of the extracellular vesicles from the complex may be performed by any method known in the art.
[0071] The type of "EV cleansing nonionic surfactant" used in the manufacturing method of the present invention, the conditions for treatment with the "EV cleansing nonionic surfactant", and the extracellular vesicle membrane-bound substance are as defined in the cleaning method of the present invention.
[0072] The production method of the present invention can be used as a method for recovering, isolating, or purifying extracellular vesicles.
[0073] The purified extracellular vesicles produced by the production method of the present invention have a reduced amount of contaminants, and therefore may be used, for example, as an analytical subject in analysis or as an EV preparation.
[0074] 4. Methods for analyzing extracellular vesicles The present invention also provides a method for analyzing extracellular vesicles.
[0075] The analytical method of the present invention involves analyzing extracellular vesicles washed by the washing method of the present invention, or a purified product of extracellular vesicles produced by the production method of the present invention (hereinafter referred to as "extracellular vesicles obtained by the present invention").
[0076] The analysis of extracellular vesicles may be an analysis of components contained in the extracellular vesicles (e.g., EV internal markers, EV surface markers), or an analysis of the particles of the extracellular vesicles themselves. The analysis of extracellular vesicles is preferably an analysis of components contained in the extracellular vesicles, and more preferably an analysis of EV internal markers. The extracellular vesicles obtained by the present invention have a reduced amount of contaminants, and can be suitably used for the analysis of components contained in the extracellular vesicles (e.g., EV internal markers).
[0077] When a component contained in an extracellular vesicle is analyzed, the analysis is the detection or quantification of the component. Such an analysis can also be the analysis of one or more components. The components to be analyzed include, for example, proteins, nucleic acids (e.g., RNA, DNA), sugars, lipids, amino acids, vitamins, polyamines, and peptides.
[0078] Analysis of the components can be performed by any method known in the art. When the component to be analyzed is a protein, the analysis method may include, for example, immunoassay and mass spectrometry. For example, immunoassay may include direct competitive method, indirect competitive method, and sandwich method. For example, such immunoassay may include chemiluminescence immunoassay (CLIA) (e.g., chemiluminescence enzyme immunoassay (CLEIA)), immunoturbidimetric method (TIA), enzyme immunoassay (EIA) (e.g., direct competitive ELISA, indirect competitive ELISA, and sandwich ELISA), radioimmunoassay (RIA), latex agglutination reaction method, fluorescent immunoassay (FIA), immunochromatography method, Western blotting, immunostaining, and fluorescence activated cell sorting (FACS). When multiple components are analyzed, proteome analysis may be performed. When the component to be analyzed is a nucleic acid, analytical methods include, for example, hybridization methods using a probe, reverse transcription (RT) reactions using reverse transcriptase, nucleic acid amplification methods using primers (e.g., 2, 3, or 4 primers) (e.g., PCR methods such as quantitative PCR and RT-PCR), sequencing, and mass spectrometry. When the components to be analyzed are components other than proteins and nucleic acids, the analytical method may include, for example, immunoassays and mass spectrometry. When multiple components are analyzed, metabolomic analysis may be performed.
[0079] The analysis method of the present invention can be used to detect markers contained in extracellular vesicles. Markers contained in extracellular vesicles include the above-mentioned EV markers (e.g., EV internal markers and EV surface markers).
[0080] Analysis of the extracellular vesicles themselves (particles) can be performed, for example, by instruments such as particle analysis instruments, electron microscopes, and flow cytometers. In this case, the number of particles of the extracellular vesicles, the size and shape of the particles, and their distribution can be analyzed.
[0081] The analytical method of the present invention may further include disrupting the extracellular vesicles obtained by the present invention, for example, when analyzing EV internal markers. In such a case, the analytical method of the present invention is carried out by the steps including the following: (1) Destroying the extracellular vesicles obtained by the present invention; and (2) To detect extracellular vesicle internal markers in disrupted extracellular vesicles.
[0082] The destruction of extracellular vesicles can be, for example, destruction by treatment with chemical substances, destruction by treatment with physical action, or a combination of these. Examples of chemical substances include extracellular vesicle-destroying substances. For example, the above-mentioned EV-destroying surfactants can be used as the extracellular vesicle-destroying substances. As the EV-destroying surfactants used for the destruction of extracellular vesicles, surfactants other than the above-mentioned EV-cleansing nonionic surfactants (e.g., alcohol ethoxylate, polyoxyethylene-polyoxypropylene block copolymers) are preferred, and nonionic surfactants with HLB less than 15 or ionic surfactants with 11 or more carbon atoms in the carbon chain are more preferred. Examples of physical actions include pressure application.
[0083] 5. Kit The present invention also provides a kit comprising: (1) EV cleansing nonionic surfactants; and (2) Extracellular vesicle membrane-bound substances.
[0084] The kit of the present invention may further include (3) an extracellular vesicle internal marker binding substance. The kit of the present invention may further include (4) an EV-disrupting surfactant.
[0085] The EV-cleaning nonionic surfactant, the extracellular vesicle membrane-binding substance, the extracellular vesicle internal marker-binding substance, and the EV-destructing surfactant contained in the kit of the present invention are as described above. The kit of the present invention is useful for, for example, easily carrying out the cleaning method of the present invention, the recovery method of the present invention, the production method of the present invention, and the analysis method of the present invention. EXAMPLES
[0086] The present invention will be described below with reference to examples, but the present invention is not limited to these examples.
[0087] Example 1: Preparation of solid-phase and labeled antibodies, and methods for measuring EV surface markers (1) Preparation of antibody-immobilized particles (immobilized antibody) In 10 mM MES buffer (pH 5.0), 0.01 g / mL of magnetic particles were added with 0.2 mg / mL of mouse anti-CD9 monoclonal antibody (Fujirebio), mouse anti-CD63 monoclonal antibody (Fujirebio), or mouse anti-CD81 monoclonal antibody (Fujirebio), which recognizes the extracellular vesicle (EV) surface markers CD9, CD63, and CD81, respectively, and incubated at 25°C for 1 hour with gentle stirring. After the reaction, the magnetic particles were collected and washed with a washing solution (50 mM Tris buffer, 150 mM NaCl2, 2.0% BSA, pH 7.2) to obtain anti-CD9 antibody-immobilized particles, anti-CD63 antibody-immobilized particles, and anti-CD81 antibody-immobilized particles. Each antibody-immobilized particle was suspended in a particle diluent (50 mM Tris buffer, 1 mM EDTA·2Na, 0.1% NaN3, 2.0% BSA, pH 7.2) to obtain each antibody-immobilized particle solution.
[0088] (2) Preparation of alkaline phosphatase-labeled antibody Desalted alkaline phosphatase (ALP) was mixed with N-(4-maleimidobutyryloxy)-succinimide (GMBS) (final concentration 0.3 mg / mL) and left to stand at 30°C for 1 hour to perform maleimidation. Next, Fab'-labeled mouse anti-CD9 monoclonal antibody, mouse anti-CD63 monoclonal antibody, or mouse anti-CD81 monoclonal antibody was mixed with maleimidated ALP at a molar ratio of 1:1 in a coupling reaction solution (100 mM phosphate buffer, 1 mM EDTA·2Na, pH 6.3) and reacted at 25°C for 1 hour. The reaction solution was purified using Superdex200 column chromatography (General Electric) to obtain ALP-labeled anti-CD9 antibody, ALP-labeled anti-CD63 antibody, and ALP-labeled anti-CD81 antibody. Each ALP-labeled antibody was suspended in a label diluent (50 mM MES buffer, 150 mM NaCl2, 0.3 mM ZnCl2, 1 mM MgCl2, 0.1% NaN3, 2.0% BSA, pH 6.8) to obtain each labeled antibody solution.
[0089] (3) Measurement of EV surface markers (CD9, CD63, and CD81) The method for measuring EV surface markers (CD9, CD63, and CD81) in the following examples is as follows. 20μL of the measurement sample was dispensed into the reaction vessel, and 50μL of anti-CD9 antibody solid-phase particle solution, anti-CD63 antibody solid-phase particle solution, or anti-CD81 antibody solid-phase particle solution was dispensed and stirred. After that, it was incubated at 37℃ for 8 minutes, and B / F separation and washing were performed. 50μL of ALP-labeled antibody corresponding to the solid-phase antibody was dispensed into the reaction vessel, and after stirring, it was incubated at 37℃ for 8 minutes, and B / F separation and washing were performed. Then, 200μL of Lumipulse (registered trademark) substrate solution (Fujirebio Co., Ltd.) containing 3-(2'-spiroadamantane)-4-methoxy-4-(3''-phosphoryloxy)phenyl-1,2-dioxetane·disodium salt (AMPPD), which is a chemiluminescent substrate, was dispensed into the reaction vessel, and after stirring, it was incubated at 37℃ for 4 minutes, and the amount of luminescence was measured with a luminometer. The actual measurements were performed using a fully automated chemiluminescent enzyme immunoassay system (Lumipulse L2400 (Fujirebio Inc.)).
[0090] The antibody immobilized on the magnetic particles and the ALP-labeled antibody were antibodies that recognize the same epitope. Since multiple CD9, CD63, or CD81 exist on a single extracellular vesicle, it is possible to measure extracellular vesicles and their markers by a sandwich immunoassay using an antibody that recognizes the same epitope as the immobilized antibody as the ALP-labeled antibody.
[0091] (Example 2: Screening of surfactants that are difficult to destroy EVs and surfactants that are effective in destroying EVs based on EV surface marker measurements) We measured the effects of various detergents on extracellular vesicles using EV surface markers as an indicator to screen detergents that are either ineffective or effective at destroying EVs. 250 μL of EDTA and EGTA-containing PBS (EDTA / EGTA / PBS) containing 0.1 w / v% of each surfactant was added to 500 μL of human serum sample (final concentrations of EDTA and EGTA after mixing with serum sample were 50 mM, pH 7.4, respectively). The mixture was rotated at 37°C for 30 minutes and used as a measurement sample. Then, the reactivity of CD9, CD63 or CD81 in the measurement sample (measurement amount of EV surface marker) was measured according to the measurement method of Example 1 (3). EDTA / EGTA / PBS without surfactant was used as a control. From the obtained count value, the ratio of the count value when each surfactant was added to the count value of the control (influence rate %) was calculated.
[0092] The results are shown in Table 2. When the reactivity was reduced by 20% or more (the effect rate was lower than 80%) compared to the control, it was determined that the extracellular vesicles were destroyed and the surfactant used was an EV-destroying surfactant. When the reactivity was not reduced by 20% or more (the effect rate was 80% or more), it was determined that the surfactant used was a surfactant that did not affect extracellular vesicles (an EV-resistant surfactant).
[0093] [Table 2-1]
[0094] [Table 2-2]
[0095] These results indicate that nonionic surfactants with an HLB of 15 or higher and linear ionic surfactants with 10 or fewer carbon atoms in the carbon chain tend to be surfactants that do not destroy extracellular vesicles (EV-resistant surfactants). These surfactants could be candidates for surfactants for cleaning extracellular vesicles. On the other hand, nonionic surfactants with an HLB of less than 15 and ionic surfactants with 11 or more carbon atoms in the carbon chain tend to be surfactants that efficiently destroy EVs (EV-destroying surfactants). These surfactants can be used to destroy extracellular vesicles.
[0096] (Example 3: Examination of surfactant concentration-dependent EV destruction and EV resistance based on EV internal marker measurement) We measured the concentration-dependent effects of various surfactants on the disruption and resistance of EVs using EV internal markers as indicators. The culture supernatant of human colon adenocarcinoma cells DU-145 cultured in serum-free medium for 3 days was centrifuged at 2,000×g for 5 minutes at 4°C, and the supernatant was filtered through a 0.22 μm filter (Millipore), and then concentrated using an Amicon Ultra-15 (Millipore). The concentrated sample was centrifuged at 20,000×g for 15 minutes at 4°C. The supernatant was then centrifuged at 100,000×g for 1 hour at 4°C. The supernatant was discarded, and PBS (pH 7.4) or 50 mM EDTA / 50 mM EGTA / PBS (PBS containing 50 mM EDTA and 50 mM EGTA, pH 7.4) was added to resuspend the precipitate. After resuspension, the sample was centrifuged at 150,000×g for 1 hour at 4°C. The supernatant was discarded, and PBS or 50 mM EDTA / 50 mM EGTA / PBS was added to resuspend the precipitate to obtain EV (DU-145). The concentration of EV (DU-145) was measured using Qubit Protein Assay (Thermo Fisher Scientific). 10 μL of 63 μg / mL EV (DU-145) was mixed with 10 μL of surfactant solution (concentration see table). After reacting for 30 minutes at room temperature, 190 μL of Lumipulse sample diluent (Fujirebio) was added. The EV internal markers (CEA and CA125) contained in this sample were measured using Lumipulse Presto CEA Reagent (Fujirebio) and Lumipulse Presto CA125-II Reagent (Fujirebio) according to the attached protocol using Lumipulse L2400 (Fujirebio).
[0097] The results are shown in Table 3. When reactivity (measured amount of EV surface marker) increased by 20% or more compared to when no surfactant was added, it was determined that the membrane of EV (DU-145) had been destroyed, causing EV internal antigens (CEA, CA125) to leak out, and the surfactant used was determined to be an EV-destructive surfactant.
[0098] [Table 3]
[0099] From these results, it was found that among nonionic surfactants with HLB15 or higher, Tergitols, Pluronics, and C8TAB, a linear ionic surfactant with a carbon chain of 10 or less carbon atoms, are surfactants that do not destroy EVs (DU-145) and do not allow antigens in EVs to leak out (EV-resistant surfactants). On the other hand, it was revealed that Tween (registered trademark) 20 and Tween 80, which are nonionic surfactants with HLB15 or higher, have the effect of destroying EVs (DU-145) (EV destruction).
[0100] (Example 4: Examination of the effect of non-ionic surfactants in suppressing adsorption of sample components to the container in the EV manipulation system) Using the amount of total residual protein as an indicator, we investigated the effect of nonionic surfactants in suppressing adsorption of sample components to the container in the EV manipulation system. In a 1.5 mL polypropylene tube (QSP) (hereinafter referred to as the "reaction tube"), 500 μL of human serum sample was added with 250 μL of EDTA / EGTA / PBS containing 1.5 w / v% of each nonionic surfactant. The surfactants used were Tween 20, Triton-X100, Tergitol 15-s-30, Brij 35, Brij 58, Pluronic F68, C8TAB, NSS, C8APS, NDSB-195, and NDSB-256. The reaction solution was rotated in the reaction tube at 37°C for 30 minutes, and then the reaction solution was removed from the reaction tube. The reaction tube from which the reaction solution was removed was washed five times with PBS as a washing solution. The washing solution after each washing was transferred to an individual new tube, and these were called "washing fractions 1 to 5". The empty reaction tube after five washings was called the "post-reaction container". The reaction vessel and washing fractions were used for BCA assay (Thermo Fisher Scientific). 1 mL of BCA solution was added to the reaction vessel and reacted at 37°C for 30 minutes. 200 μL of BCA solution was added to 20 μL of washing fractions 1 to 5 and reacted at 37°C for 30 minutes. After the reaction, the absorbance at 562 nm was measured with a microplate reader (TECAN) to measure the total protein amount.
[0101] The results are shown in Table 4. The addition of all of the nonionic surfactants evaluated reduced the total amount of protein eluted in the wash fraction and reduced the total amount of protein remaining in the container.
[0102] [Table 4]
[0103] These results demonstrated that adding a nonionic surfactant to the reaction solution can reduce the inclusion of contaminants in the obtained EV sample.
[0104] (Example 5: Examination of the effect of non-ionic surfactants in suppressing adsorption of sample components to the container during EV recovery by immunoprecipitation) Using the amount of residual total protein as an indicator, we investigated the effectiveness of washing sample components with nonionic detergents during EV recovery by immunoprecipitation. In a 1.5 mL polypropylene tube (QSP) (hereinafter referred to as the "reaction tube"), 250 μL of EDTA / EGTA / PBS was added to 500 μL of human serum sample, and anti-CD9 antibody solid-phase particles were added to a concentration of 0.15 w / v%. The reaction solution was rotated in the reaction tube at 37°C for 30 minutes, and then magnetically collected and the supernatant was removed. The magnetic particles after the reaction were washed five times using PBS containing 0.05 w / v% of each surfactant as a washing solution. The surfactant used was the same as in Example 4. The washing solutions after each washing were transferred to separate new tubes, and these were designated as "washing fractions 1 to 5". The magnetic particles after washing were transferred to another new tube. The reaction tube was washed once with the washing solution of each condition, and designated as the "post-sedimentation container". The post-sedimentation container and washing fractions 1 to 5 were used for the BCA assay (Thermo Fisher Scientific). After precipitation, 1 mL of BCA solution was added to the container and reacted for 30 minutes at 37° C. 200 μL of BCA solution was added to 20 μL of the washed fraction and reacted for 30 minutes at 37° C. After the reaction, the absorbance at 562 nm was measured using a microplate reader (TECAN) to measure the total protein amount.
[0105] The results are shown in Table 5. When any of the nonionic surfactants evaluated were added to the washing solution, the total amount of protein eluted in the washing fraction tended to increase, while the total amount of protein remaining in the container decreased. In particular, Tween 20, Triton X-100, Tertitol 15-S-30, Brij 35, and Brij 58 showed high washing effects.
[0106] [Table 5]
[0107] These results indicate that washing with the addition of a nonionic surfactant reduces the inclusion of contaminants in the obtained EV sample.
[0108] (Example 6: Examination of the concentration dependence of the washing effect with non-ionic detergent in EV recovery by immunoprecipitation) Using the amount of residual total protein as an indicator, we evaluated the concentration dependence of the washing effect of nonionic detergents in EV recovery by immunoprecipitation. In a 1.5 mL polypropylene tube (QSP) (hereinafter referred to as the "reaction tube"), 250 μL of EDTA / EGTA / PBS was added to 500 μL of human serum sample, and anti-CD9 antibody solid-phased particles were added thereto so as to be 0.15 w / v%. The reaction solution was rotated in the reaction tube at 37 °C for 30 minutes, then magnetically collected, and the supernatant was transferred to another new tube. The magnetic particles after the reaction were washed five times with PBS containing Tergitol 15-s-30 or Pluronic F68 at each concentration (0 w / v%, 0.01 w / v%, 0.05 w / v%, 0.1 w / v%, 0.25 w / v%, 0.5 w / v%, 1.0 w / v%) as a washing solution. The washed magnetic particles were transferred to another new tube. The reaction tube was washed once with the washing solution of each condition, and used as the "container after precipitation". The container after precipitation was used for BCA assay (Thermo Fisher Scientific). 1 mL of BCA solution was added to the container after precipitation, and reacted at 37°C for 30 minutes. After the reaction, the absorbance at 562 nm was measured with a microplate reader (TECAN) to measure the total protein amount.
[0109] The results are shown in Table 6 and Figure 1. By adding Tergitol 15-s-30 or pluronic F68 to the cleaning solution at 0.01% or more, the amount of sample components (residual total protein) adsorbed to the container decreased, indicating a cleaning effect. In particular, Tergitol 15-s-30 showed a higher cleaning effect.
[0110] [Table 6]
[0111] These results indicate that washing with the addition of Tergitol 15-s-30 further reduces the inclusion of contaminants in the obtained EV samples.
[0112] (Example 7: Examination of the washing effect in recovery of EVs from samples) We investigated the effectiveness of washing in recovering EVs from samples. In a 1.5 mL polypropylene tube (QSP) (hereafter referred to as the "reaction tube"), 250 μL of EDTA / EGTA / PBS was added to 500 μL of human serum sample, and anti-CD9 antibody solid-phased particles were added to the mixture at 0.15 w / v%. The reaction solution was rotated in the reaction tube at 37°C for 30 minutes, then magnetically collected, and the supernatant was transferred to another new tube. The resulting supernatant was designated as the "SUP sample". The magnetic particles after the reaction were washed five times with PBS (pH 7.4) or PBS containing Tergitol15-s-30 (0.05 w / v% Tergitol15-s-30, pH 7.4) as the washing solution. The washing solutions after each washing were transferred to individual new tubes, and these were designated as "washing fractions 1 to 5". The washed magnetic particles were transferred to another new tube and designated as "particles after precipitation". The reaction tube was washed once with the washing solution of each condition, and designated as the "container after precipitation". The post-sedimentation particles, the post-sedimentation container, and the washing fractions were used for BCA assay (Thermo Fisher Scientific). 1 mL of BCA solution was added to the post-sedimentation particles and the post-sedimentation container, and the reaction was allowed to proceed at 37°C for 30 minutes. 200 μL of BCA solution was added to 20 μL of washing fractions 1 to 5, and the reaction was allowed to proceed at 37°C for 30 minutes. After the reaction, the absorbance at 562 nm was measured with a microplate reader (TECAN) to measure the total protein amount. For the SUP samples and washing fractions, the CEA amount was measured with Lumipulse Presto CEA Reagent (Fujirebio) using Lumipulse L2400 (Fujirebio).
[0113] The results of total protein measurement by BCA assay are shown in Table 7, and the results of CEA measurement are shown in Table 8. By adding Tergitol15-s-30 to the washing solution, the total protein amount eluted in the washing fraction increased compared to the case of no addition, and the total protein amount remaining in the container after immunization decreased to 62.3%. Furthermore, by adding Tergitol15-s-30 to the washing solution, the amount of CEA eluted in the washing fraction increased and the amount of CEA remaining in the container decreased.
[0114] [Table 7]
[0115] [Table 8]
[0116] These results indicate that washing with Tergitol 15-s-30 reduces the inclusion of contaminants in the obtained EV samples.
[0117] (Example 8: Confirmation of cleaning effect by EV marker measurement) EVs were collected from the samples, disrupted, and markers in the EVs were measured. In a 1.5 mL polypropylene tube (QSP) (hereafter referred to as the "reaction tube"), 250 μL of EDTA / EGTA / PBS was added to 500 μL of human serum sample, which was used as the "undiluted sample". Anti-CD9 antibody-immobilized particles, anti-CD63 antibody-immobilized particles, anti-CD81 antibody-immobilized particles, or a mixture of these was added to the undiluted sample so that the concentration was 0.15 w / v%. The reaction solution was rotated in the reaction tube at 37°C for 30 minutes, then magnetically collected, and the supernatant was transferred to another new tube. These were used as the "SUP sample". After the reaction, the magnetic particles were washed five times with PBS containing 0.05% Tergitol15-S-30 as a washing solution. The washing solutions after each washing were transferred to separate new tubes, and these were used as "washing fractions 1 to 5". 20 μL of lysis buffer (D-PBS(-), 150 mM NaCl, 1.0% N-lauroyl sarcosine sodium, 2.0% N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, pH 7.4) was added to the container (reaction tube) containing the washed magnetic particles. The reaction was carried out at room temperature for 5 minutes to dissolve the extracellular vesicles. After that, the particles were collected and the supernatant was diluted with 180 μL of Lumipulse sample diluent (Fujirebio) to obtain a "lysis sample."
[0118] First, to confirm that extracellular vesicles in the raw sample were recovered by immunoprecipitation using antibodies that specifically bind to EV surface markers (CD9, CD63, and CD81), the EV surface markers in the raw sample and SUP sample were measured by the measurement method of Example 1. As a blank, Lumipulse sample dilution solution (Fujirebio Co., Ltd.) was measured in the same manner. From the obtained count value, the EV recovery rate (= (1-(SUP sample-blank) / (raw sample-blank)) x 100 (%)) was calculated.
[0119] The results are shown in Table 9. As a result, the recovery rates of EVs recovered by immunoprecipitation using anti-CD9 antibody, anti-CD63 antibody, and anti-CD81 antibody were all over 90%, confirming that EVs from serum samples can be recovered by immunoprecipitation. It was also found that the efficiency of EV recovery can be evaluated using a fully automated chemiluminescent enzyme immunoassay system.
[0120] [Table 9]
[0121] Next, the reactivity of CEA in the original solution sample, SUP sample and Lysis sample was measured in the same manner as in Example 3. In this measurement, samples obtained by immunoprecipitation using a mixture of anti-CD9 antibody-immobilized particles, anti-CD63 antibody-immobilized particles and anti-CD81 antibody-immobilized particles were used as the SUP sample and Lysis sample. In addition, in order to confirm that the reactivity of CEA in the Lysis sample was a specific reaction to CEA, an inhibition test was performed. Specifically, an antibody that recognizes the same region as the epitope region of the anti-CEA antibody used in the Lumipulse Prest CEA reagent was added to the CEA reagent, and CEA was measured in the same manner as in Example 3 (inhibition count).
[0122] The results are shown in Table 10. As a result of measuring CEA, the luminescence intensity of the undiluted sample and the SUP sample was around 2,000,000 counts, indicating that the serum sample contained a large amount of CEA. On the other hand, the luminescence intensity of the Lysis sample was 2,025 counts, indicating that the amount of CEA derived from EVs was very small compared to the CEA contained in the serum sample, and that the method of the present invention can measure CEA derived from EVs. When CEA was measured again, the count value of the Lysis sample was 1,950 counts, confirming reproducibility.
[0123] [Table 10]
[0124] As a result of the inhibition test, the luminescence intensity of the lysis sample was 890 counts. Since the inhibition rate (= ((1-(inhibition count-blank count) / (lysis sample count-blank count)) x 100(%)) was over 90%, it was confirmed that the CEA reactivity of the lysis sample was a specific reaction to CEA. When the same experiment was performed again, the reactivity of the lysis was 1589 counts, and the inhibition test count was 837 counts, resulting in an inhibition rate of over 90%, confirming reproducibility.
[0125] Furthermore, when a similar test was performed using magnetic particles with no antibody bound (unsensitized particles), the luminescence intensity of the lysis sample was 824 counts, indicating no reactivity to CEA. Therefore, it was found that the nonspecific adsorption of CEA contained in the specimen to the magnetic particles can be suppressed by adding a specific nonionic surfactant to the washing solution.
[0126] These results demonstrated that by adding a specific nonionic surfactant to the washing solution, it is possible to specifically extract extracellular vesicles from human specimens and specifically detect CEA in the extracellular vesicles.
Claims
1. The extracellular vesicles are represented by the following formula (I): 【Chemistry 1】 [Wherein, x is 15 to 100; y is an integer equal to or greater than 0; z is an integer equal to or greater than 0; y≧z; and y+z is 5 to 30.
2. The method of claim 1 , wherein y and z are each an integer greater than or equal to 1.
3. The method according to claim 1 or 2, wherein after sedimentation of the extracellular vesicles with the extracellular vesicle membrane-binding substance, the extracellular vesicles are washed with the non-ionic detergent.
4. The method according to any one of claims 1 to 3, wherein the nonionic surfactant is an alcohol ethoxylate having an HLB of 15 or more or a carbon chain having 16 or fewer carbon atoms.
5. The method further comprises: (1) Treating extracellular vesicles with an extracellular vesicle membrane-binding substance to form a complex between the extracellular vesicles and the extracellular vesicle membrane-binding substance; and (2) washing the complex with the nonionic surfactant; The method according to any one of claims 1 to 4, comprising the steps of:
6. (1) The method according to claim 5, wherein treating extracellular vesicles with an extracellular vesicle membrane-binding substance to form a complex between the extracellular vesicles and the extracellular vesicle membrane-binding substance is carried out by causing the formation of a complex between the extracellular vesicles and the extracellular vesicle membrane-binding substance and its precipitation by a precipitation method using a solid phase bound to the extracellular vesicle membrane-binding substance.
7. The method according to any one of claims 1 to 6, wherein the extracellular vesicles are treated with 0.001 to 10.0 w / v % of the non-ionic detergent.
8. The method according to any one of claims 1 to 7, wherein the extracellular vesicles are exosomes.
9. The method according to any one of claims 1 to 8, wherein the extracellular vesicle membrane-binding substance is an antibody against a tetraspanin membrane protein.
10. A method for producing a purified extracellular vesicle, comprising: (1) The extracellular vesicles are prepared by the method according to the following formula (I): 【Chemistry 2】 [Wherein, x is 15 to 100; y is an integer equal to or greater than 0; z is an integer equal to or greater than 0; y≧z; and y+z is 5 to 30. (2) Isolating the washed extracellular vesicles.
11. The method of claim 10, wherein after sedimentation of the extracellular vesicles with the extracellular vesicle membrane-binding substance, the extracellular vesicles are washed with the non-ionic detergent.
12. The method according to claim 10 or 11, which is carried out by the steps comprising: (1') treating the extracellular vesicles with an extracellular vesicle membrane-binding substance to form a complex between the extracellular vesicles and the extracellular vesicle membrane-binding substance; (2') washing the complex with the nonionic detergent; and (3') isolating the complex.
13. (1') The method according to claim 12, wherein treating extracellular vesicles with an extracellular vesicle membrane-binding substance to form a complex between the extracellular vesicles and the extracellular vesicle membrane-binding substance is carried out by causing the formation of a complex between the extracellular vesicles and the extracellular vesicle membrane-binding substance and its precipitation by a precipitation method using a solid phase bound to the extracellular vesicle membrane-binding substance.
14. (A) (1) Obtaining washed extracellular vesicles by the method according to any one of claims 1 to 9, or (2) Obtaining a purified product of extracellular vesicles by the method according to any one of claims 10 to 13; and (B) A method for analyzing extracellular vesicles, comprising analyzing the washed extracellular vesicles or extracellular vesicle purification product obtained by (A).
15. The method of claim 14, wherein the analysis is performed by detection of an extracellular vesicle internal marker.
16. The method of claim 15, wherein the extracellular vesicle internal marker is carcinoembryonic antigen (CEA) or CA125.
17. The method according to any one of claims 14 to 16, which is carried out by a process comprising the steps of: (1) Destroying extracellular vesicles washed by the method according to any one of claims 1 to 9, or a purified product of extracellular vesicles produced by the method according to any one of claims 10 to 13; and (2) Detecting extracellular vesicle internal markers in disrupted extracellular vesicles.
18. below: (1) The following formula (I): 【Chemistry 3】 [Wherein, x is 15 to 100; y is an integer equal to or greater than 0; z is an integer equal to or greater than 0; y≧z; and y+z is 5 to 30. (2) Extracellular vesicle membrane-bound substances Including, The kit may further comprise a solid phase.
Citation Information
Patent Citations
Preparation of therapeutic exosomes using membrane proteins
US20190117792A1
Separation method, detection method, signal measurement method, method for determining disease, method for evaluating drug efficacy of disease treatment drug, kit, and liquid composition
WO2015068772A1
Method for analyzing nucleic acid
WO2018062263A1
Cancer diagnosis device
WO2018207932A1
